Table 2.
Cardiovascular outcomes trials in diabetes
| Clinical Trial.gov ID | Drug | Trial short namea | Sample size | Start date |
|---|---|---|---|---|
| Sodium glucose cotransporter 2 (SGLT2) inhibitors | ||||
| NCT0103262983 | Canagliflozin | CANVAS | 4,330 | Dec 2009 |
| NCT01131676 | Empagliflozin | EMPA-REG OUTCOME | 7,000 | Jul 2010 |
| NCT01730534 | Dapagliflozin | DECLARE-TIMI 58 | 17,150 | Apr 2013 |
| NCT01986881 | Ertugliflozin | 3,900 | Nov 2013 | |
| Dipeptidyl peptidase-4 (DPP-4) inhibitors | ||||
| NCT00790205 | Sitagliptin | TECOS | 14,000 | Dec 2008 |
| NCT0096870880 | Alogliptin | EXAMINE | 5,380 | Oct 2009b |
| NCT0110788681 | Saxagliptin | SAVOR-TIMI 53 | 16,492 | May 2010b |
| NCT0124342484 | Linagliptin | CAROLINA | 6,000 | Oct 2010 |
| NCT01703208 | MK-3102 | 4,000 | Oct 2012 | |
| NCT01897532 | Linagliptin | CARMELINA | 8,300 | Jul 2013 |
| Glucagon like peptide-1 (GLP-1) agonists | ||||
| NCT01018173 | Taspoglutide | T-emerge 8 | 2,118 | Jan 2010c |
| NCT01147250 | Lixisenatide | ELIXA | 6,000 | Jun 2010 |
| NCT01144338 | Exenatide | EXSCEL | 14,000 | Jun 2010 |
| NCT0117904885 | Liraglutide | LEADER | 9,340 | Aug 2010 |
| NCT01394952 | Dulaglutide | REWIND | 9,622 | Jul 2011 |
| NCT01720446 | Semaglutide | SUSTAIN 6 | 3,260 | Feb 2013 |
| NCT01455896 | ITCA 650 | 2,000 | Mar 2013 | |
| Others | ||||
| NCT0070085686 | Pioglitazone versus SU | TOSCA IT | 3,371 | Sep 2008 |
| NCT0087997087 | Rosiglitazone/pioglitazone | TIDE | 1,332 | May 2009c |
| NCT0104276988 | Aleglitazar | AleCardio | 7,228 | Jan 2010c |
| NCT01715818 | Aleglitazar | AlePrevent | 1,999 | Dec 2012c |
| NCT0006978489 | Insulin glargine | ORIGIN | 12,537 | Aug 2003b |
| NCT01959529 | Insulin degludec | 7,500 | Oct 2013 | |
| NCT00829660 | Acarbose | ACE | 7,500 | Feb 2009 |
| NCT01609582 | Fasiglifam (TAK-875) | GRAND 306 | 5,000 | Jun 2012 |